Literature DB >> 10496870

Development and characterization of a Staphylococcus aureus nasal colonization model in mice.

K B Kiser1, J M Cantey-Kiser, J C Lee.   

Abstract

Staphylococcus aureus nasal carriage is a risk factor for infection in humans, particularly in the hospital environment. Attenuation of carriage has proven effective in reducing the prevalence of infection in some high-risk groups. To study staphylococcal factors that influence nasal colonization, a mouse model of S. aureus nasal colonization was developed. Mice were inoculated intranasally with S. aureus Reynolds, and nasal carriage was evaluated by quantitating cultures of the nasal tissues from mice sacrificed at various time points after inoculation. The majority of mice inoculated with 10(8) CFU of S. aureus maintained nasal carriage for at least 20 days. Nasal colonization rates were similar for inbred (BALB/c and C57BL/6) and outbred (ICR) mice. Colonization was not affected by mouse passage of strain Reynolds. Lower inoculum doses (<10(7) CFU) resulted in reduced colonization after 7 days. However, mice given streptomycin in their drinking water developed long-term carriage of S. aureus, and they were colonized with inocula as low as 10(5) CFU. Nasal colonization was also established with two other S. aureus strains (one strain each of human and murine origins). S. aureus recovered from the nares of experimentally colonized mice expressed high levels of capsule, and the ability of a capsule-defective mutant to persist in the nares was reduced in comparison to that of the parent strain. This nasal colonization model should prove useful for studies of factors that mediate S. aureus colonization and for assessment of targets for antimicrobial intervention or vaccine development.

Entities:  

Mesh:

Year:  1999        PMID: 10496870      PMCID: PMC96845          DOI: 10.1128/IAI.67.10.5001-5006.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

Review 1.  Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks.

Authors:  J Kluytmans; A van Belkum; H Verbrugh
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Regulation of Staphylococcus aureus capsular polysaccharide type 5: CO2 inhibition in vitro and in vivo.

Authors:  S Herbert; D Worlitzsch; B Dassy; A Boutonnier; J M Fournier; G Bellon; A Dalhoff; G Döring
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

3.  Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus.

Authors:  J A Kluytmans; J W Mouton; M F VandenBergh; M J Manders; A P Maat; J H Wagenvoort; M F Michel; H A Verbrugh
Journal:  Infect Control Hosp Epidemiol       Date:  1996-12       Impact factor: 3.254

4.  Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae.

Authors:  H Y Wu; M H Nahm; Y Guo; M W Russell; D E Briles
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

5.  Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results.

Authors:  M Pérez-Fontán; T García-Falcón; M Rosales; A Rodríguez-Carmona; M Adeva; I Rodríguez-Lozano; J Moncalián
Journal:  Am J Kidney Dis       Date:  1993-11       Impact factor: 8.860

6.  Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus.

Authors:  J C Lee; S Takeda; P J Livolsi; L C Paoletti
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

7.  Elimination of Staphylococcus aureus in hemodialysis patients.

Authors:  J Bommer; W Vergetis; K Andrassy; V Hingst; M Borneff; W Huber
Journal:  ASAIO J       Date:  1995 Jan-Mar       Impact factor: 2.872

8.  Staphylococcus aureus binding to human nasal mucin.

Authors:  J Shuter; V B Hatcher; F D Lowy
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

9.  Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage.

Authors:  B N Doebbeling; D R Reagan; M A Pfaller; A K Houston; R J Hollis; R P Wenzel
Journal:  Arch Intern Med       Date:  1994-07-11

10.  EPIDEMIOLOGY AND PATHOGENESIS OF STAPHYLOCOCCAL INFECTION. I. AN EXPERIMENTALLY INDUCED ATTENUATED STAPHYLOCOCCAL INFECTION IN GUINEA PIGS AND ITS MODIFICATION BY TETRACYCLINE.

Authors:  H J SIMON
Journal:  J Exp Med       Date:  1963-08-01       Impact factor: 14.307

View more
  59 in total

1.  Regulation of Staphylococcus aureus capsular polysaccharide expression by agr and sarA.

Authors:  Thanh Luong; Subrata Sau; Marisa Gomez; Jean C Lee; Chia Y Lee
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  Constitutive production of catalytic antibodies to a Staphylococcus aureus virulence factor and effect of infection.

Authors:  Eric L Brown; Yasuhiro Nishiyama; Jesse W Dunkle; Shreya Aggarwal; Stephanie Planque; Kenji Watanabe; Keri Csencsits-Smith; M Gabriela Bowden; Sheldon L Kaplan; Sudhir Paul
Journal:  J Biol Chem       Date:  2012-02-02       Impact factor: 5.157

Review 3.  Staphylococcal adaptation to diverse physiologic niches: an overview of transcriptomic and phenotypic changes in different biological environments.

Authors:  Sana S Dastgheyb; Michael Otto
Journal:  Future Microbiol       Date:  2015-11-19       Impact factor: 3.165

4.  Staphylococcus colonization of the skin and antimicrobial peptides.

Authors:  Michael Otto
Journal:  Expert Rev Dermatol       Date:  2010-04

5.  Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.

Authors:  Lorena P N Tuchscherr; Fernanda R Buzzola; Lucía P Alvarez; Jean C Lee; Daniel O Sordelli
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

6.  Staphylococcus aureus Cap5O has UDP-ManNAc dehydrogenase activity and is essential for capsule expression.

Authors:  M Portolés; K B Kiser; N Bhasin; K H Chan; J C Lee
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

7.  Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus.

Authors:  Anu Daniel; Chad Euler; Mattias Collin; Peter Chahales; Kenneth J Gorelick; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

8.  Clearance of Staphylococcus aureus nasal carriage is T cell dependent and mediated through interleukin-17A expression and neutrophil influx.

Authors:  Nathan K Archer; Janette M Harro; Mark E Shirtliff
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

9.  Regulatory adaptation of Staphylococcus aureus during nasal colonization of humans.

Authors:  Marc Burian; Christiane Wolz; Christiane Goerke
Journal:  PLoS One       Date:  2010-04-06       Impact factor: 3.240

10.  Identification of Unique Blood and Urine Biomarkers in Influenza Virus and Staphylococcus aureus Co-infection: A Preliminary Study.

Authors:  Meagan A Prescott; Manoj K Pastey
Journal:  Biomark Insights       Date:  2010-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.